NeoCore Technology Co., Ltd.

TPEX:4131 Stock Report

Market Cap: NT$1.3b

NeoCore Technology Past Earnings Performance

Past criteria checks 0/6

NeoCore Technology's earnings have been declining at an average annual rate of -33.5%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 8.8% per year.

Key information

-33.5%

Earnings growth rate

-16.5%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate-8.8%
Return on equity-25.7%
Net Margin-95.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

DR.Chip Biotechnology Incorporation (GTSM:4131) Is Carrying A Fair Bit Of Debt

Apr 19
DR.Chip Biotechnology Incorporation (GTSM:4131) Is Carrying A Fair Bit Of Debt

DR.Chip Biotechnology Incorporation (GTSM:4131) Is Carrying A Fair Bit Of Debt

Jan 04
DR.Chip Biotechnology Incorporation (GTSM:4131) Is Carrying A Fair Bit Of Debt

Revenue & Expenses Breakdown

How NeoCore Technology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4131 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2468-656017
30 Jun 2466-715723
31 Mar 2461-715625
31 Dec 2365-655125
30 Sep 2374-504821
30 Jun 2381-394613
31 Mar 2380-34449
31 Dec 2289-28457
30 Sep 2288-29446
30 Jun 2285-25446
31 Mar 2293-19436
31 Dec 2189-17426
30 Sep 2186-18436
30 Jun 2194-18445
31 Mar 2197-20465
31 Dec 2093-27476
30 Sep 2096-28496
30 Jun 2097-20496
31 Mar 2097-18507
31 Dec 19104-12547
30 Sep 1999-12448
30 Jun 19100-21469
31 Mar 1987-24438
31 Dec 1862-25338
30 Sep 1842-22338
30 Jun 1818-22248
31 Mar 1812-22197
31 Dec 1712-21207
30 Sep 1714-252010
30 Jun 1716-272010
31 Mar 1716-282010
31 Dec 1617-282111
30 Sep 1618-202110
30 Jun 1619-172010
31 Mar 1620-182111
31 Dec 1522-172111
30 Sep 1526-192412
30 Jun 1526-222514
31 Mar 1527-232516
31 Dec 1427-222518
30 Sep 1424-303020
30 Jun 1423-434122
31 Mar 1446-444124
31 Dec 1361-454225

Quality Earnings: 4131 is currently unprofitable.

Growing Profit Margin: 4131 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4131 is unprofitable, and losses have increased over the past 5 years at a rate of 33.5% per year.

Accelerating Growth: Unable to compare 4131's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4131 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).


Return on Equity

High ROE: 4131 has a negative Return on Equity (-25.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:13
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeoCore Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution